- Home
- CRON vs JANX Comparison
CRON vs JANX Comparison
Compare CRON & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | JANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | N/A | 109 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.4M | 890.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRON | JANX |
|---|---|---|
| Price | $2.80 | $14.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $57.36 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $132,357,000.00 | $10,000,000.00 |
| Revenue This Year | $17.63 | N/A |
| Revenue Next Year | $30.76 | N/A |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $1.60 | $12.80 |
| 52 Week High | $3.43 | $47.58 |
Technical Indicators
Market Signals| Indicator | CRON | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 47.85 |
| Support Level | $2.50 | $12.80 |
| Resistance Level | $2.80 | $14.34 |
| Average True Range (ATR) | 0.09 | 0.63 |
| MACD | 0.00 | 0.48 |
| Stochastic Oscillator | 86.36 | 79.55 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.